Orforglipron compared with dulaglutide in children and teens with type 2 diabetes
Compares orforglipron with dulaglutide in young people who have type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Key facts
- Where
- Ciudad Madero, Guadalajara, and Monterrey, MexicoSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 10 to 17 with type 2 diabetes. It compares a daily pill, orforglipron, with a weekly injection, dulaglutide.
- Age
- 10 to 17 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes treated with diet and exercise and metformin and/or basal insulin. HbA1c above 6.5% (48 mmol/mol) and up to 11.0% (97 mmol/mol) at screening.
- Earlier treatment
- Before screening, people can be on metformin and/or basal insulin. They cannot have used other glucose-lowering medicines, except SGLT2 inhibitors, within 90 days before screening. They cannot have used weight-loss medicines within 90 days before screening.
- Biomarker or test result
- HbA1c above 6.5% (48 mmol/mol) and up to 11.0% (97 mmol/mol) at screening. Body weight of at least 50 kg (110 lb) and BMI above the 85th percentile.
Main reasons for not taking part
- Type 1 diabetes
- Past diabetic ketoacidosis or hyperosmolar syndrome after the type 2 diabetes diagnosis
- Severe low blood sugar or unawareness of low blood sugar in the last 6 months
- History of pancreatitis or gallbladder disease
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 17 years old?
Source: NCT07668336, who can take part
Where in Mexico
- Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C.Ciudad Madero, MexicoNot yet recruiting
- Centro de Investigacion Medica de Occidente, S.C.Guadalajara, MexicoNot yet recruiting
- Centro de investigación y control metabólicoMonterrey, MexicoNot yet recruiting
- Clínica García Flores SCMonterrey, MexicoNot yet recruiting
- UBAM Unidad Biomedica Avanzada MonterreyMonterrey, MexicoNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07668336EU 2025-524811-35-00
- Record updated
- 5 November 2026
- Original description
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them.Read full original descriptionShow less
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them.
Participation in the study will last about 61 weeks.
Inclusion: Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin; Have HbA1c > 6.5% to ≤ 11.0% at screening; Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of >85th percentile.
Exclusion: Have had at least one episode of severe hypoglycemia and/or at least one episode of hypoglycemic unawareness within the last 6 months before screening; Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 90 days prior to screening; Have type 1 diabetes; After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome; Have a history of pancreatitis or gallbladder disease; Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2); Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or (SGLT2) inhibitors within 90 days prior to screening.